BCMA CAR-T FOR MYELOMA
IN CHINA
China has the world's most active BCMA CAR-T myeloma programme โ two approved products, multiple academic trials, and costs 40โ60% below Western pricing.
analyticsAt a Glance
- check_circleBCMA (B-cell maturation antigen) is expressed on virtually all myeloma cells
- check_circleBCMA CAR-T achieves MRD-negativity in a significant proportion of relapsed myeloma patients
- check_circleChina offers approved and trial BCMA CAR-T options at 40โ70% lower cost than Western centres
- check_circleRequires 4โ6 weeks manufacturing time; bridging therapy may be needed in the interim
China BCMA CAR-T โ Key Numbers
- โฅ90%CR RatesIn r/r myeloma selected populations
- 2Approved ProductsCarvykti and equecabtagene autoleucel
- 40โ60%Cost Savingvs USA/Europe pricing
- $130Kโ160KCarvykti Costvs $465,000 in USA
BCMA CAR-T Products in China
| Product | Company | Status | China Cost (USD) |
|---|---|---|---|
| Carvykti (ciltacabtagene) | Janssen/Legend Biotech | NMPA approved | $130,000โ160,000 |
| Equecabtagene (CT053) | Juventas/IASO Bio | NMPA approved | $90,000โ130,000 |
| CT103A (fully human BCMA) | IASO Bio | Clinical trial | Trial subsidised |
| BCMA+GPRC5D dual-target | Multiple | Clinical trial | Trial subsidised |
Patient Selection
BCMA CAR-T in China is available for r/r myeloma after โฅ1 prior line including PI and IMiD.
Standard Eligibility
r/r myeloma after โฅ1 prior line including PI + IMiD. ECOG PS 0โ1. Adequate organ function. No active serious infection. Carvykti: โฅ1 prior line.
Post-BCMA Options
For patients who have relapsed after BCMA CAR-T, GPRC5D CAR-T or bispecifics (talquetamab) are the main options. China has active GPRC5D trials.
Frequently Asked Questions
BCMA CAR-T in China
What is the difference between Carvykti and equecabtagene?
Both are BCMA-directed CAR-T approved in China. Carvykti is developed by Janssen/Legend using a VHH camelid-derived binding domain. Equecabtagene (CT053/Carteyva) is China-developed with a fully human BCMA scFv โ potentially lower immunogenicity. Both have ORR exceeding 90% in r/r myeloma.
Can CancerFax coordinate BCMA CAR-T access in China?
Yes. CancerFax reviews your myeloma history, prior treatment lines, BCMA expression, and organ function to identify the most appropriate product or trial at Chinese centres. We coordinate eligibility confirmation, leukapheresis scheduling, and travel logistics.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Myeloma CAR-T in China?
CancerFax reviews your myeloma history to identify the most appropriate BCMA CAR-T product or trial at Chinese centres.
This information is for patient education only. Consult a qualified haematologist before making treatment decisions.